Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 2/2017

01-04-2017 | Original Investigation

MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients

Authors: Sajad Varmazyar, Sayed Mahdi Marashi, Zabihollah Shoja, Maria Lina Tornesello, Franco M. Buonaguro, Shohreh Shahmahmoodi, Zahra Safaie-Naraghi, Somayeh Jalilvand

Published in: Medical Microbiology and Immunology | Issue 2/2017

Login to get access

Abstract

A single-nucleotide polymorphism (SNP) in the promoter region of MDM2 (SNP309T>G, rs2279744) has been shown to increase the expression of the MDM2 protein in various cancer types. However, only one study has analyzed the role of the MDM2 polymorphism in the development of Kaposi’s sarcoma (KS). The association of MDM2 SNP309 with classic KS risk was evaluated in 79 Iranian patients with classic KS and 123 healthy controls. The MDM2 SNP309 was genotyped using PCR and restriction fragment length polymorphism methods. No significant correlation was found between the SNP309 polymorphism in MDM2 promoter and classic KS risk. There was no significant correlation between gender and disease stage. However, a significant association was found between SNP309 GG genotype and younger age (≤50 years) (odds ratio 9.5, 95% confidence intervals 1.5–60, p = 0.03). Our findings support no major role for the MDM2 SNP309 in KS development although it might influence the clinical outcome of KS in younger patients.
Literature
1.
Buonaguro FM, Tornesello ML, Buonaguro L, Satriano RA, Ruocco E, Castello G, Ruocco V (2003) Kaposi’s sarcoma: aetiopathogenesis, histology and clinical features. J Eur Acad Dermatol Venereol 17(2):138–154PubMedCrossRef
2.
Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R (2000) Classic kaposi sarcoma: epidemiology and risk factors. Cancer 88(3):500–517PubMedCrossRef
3.
Kaposi M (1872) Idiopathisches multiples pigmentsarkom her haut. Arch Dermatol Shypilol 4:265–273CrossRef
4.
Buonaguro FM, Tornesello ML, Beth-Giraldo E, Hatzakis A, Mueller N, Downing R, Biryamwaho B, Sempala SD, Giraldo G (1996) Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi’s sarcoma (KS) biopsies. Int J Cancer 65(1):25–28PubMedCrossRef
5.
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266(5192):1865–1869PubMedCrossRef
6.
7.
Reinheimer C, Allwinn R, Sturmer M (2011) Do fewer cases of Kaposi’s sarcoma in HIV-infected patients reflect a decrease in HHV8 seroprevalence? Med Microbiol Immunol 200(3):161–164PubMedCrossRef
8.
Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff C, Rainbow L, Howard MR, Gao SJ, Bohenzky RA, Simmonds P, Lee C, de Ruiter A, Hatzakis A, Tedder RS, Weller IV, Weiss RA, Moore PS (1996) Prevalence of Kaposi’s sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. The Lancet 348(9035):1133–1138CrossRef
9.
Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, Newton R, Rinaldo CR, Saah A, Phair J, Detels R, Chang Y, Moore PS (1996) KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. Nat Med 2(8):925–928PubMedCrossRef
10.
de Souza V, Sumita LM, Nascimento MC, Oliveira J, Mascheretti M, Quiroga M, Freire WS, Tateno A, Boulos M, Mayaud P, Pannuti CS (2007) Human herpesvirus-8 infection and oral shedding in Amerindian and non-Amerindian populations in the Brazilian Amazon region. J Infect Dis 196(6):844–852PubMedPubMedCentralCrossRef
11.
Jalilvand S, Shoja Z, Marashi SM, Shahmahmoodi S, Safaie-Naraghi Z, Nourijelyani K, Nesheli AB, Mokhtari-Azad T (2015) Mitochondrial haplogroups and control region polymorphisms in Kaposi’s sarcoma patients. J Med Virol 87(9):1608–1615PubMedCrossRef
12.
Kakavand-Ghalehnoei R, Shoja Z, Najafi A, Mollahoseini MH, Shahmahmoodi S, Marashi SM, Nejati A, Jalilvand S (2016) Prevalence of human herpesvirus-8 among HIV-infected patients, intravenous drug users and the general population in Iran. Sex Health 13(3):295–298PubMed
13.
Jalilvand S, Shoja Z, Mokhtari-Azad T, Nategh R, Gharehbaghian A (2011) Seroprevalence of Human herpesvirus 8 (HHV-8) and incidence of Kaposi’s sarcoma in Iran. Infect Agent Cancer 6:5PubMedPubMedCentralCrossRef
14.
15.
Mousavi SM, Mohagheghi MA, Jerrahi AM (2007) Epidemiology of Kaposi’s sarcoma in Iran: 1984–2006. Asian Pac J Cancer Prev 8(4):557–560PubMed
16.
17.
Freedman DA, Wu L, Levine AJ (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55(1):96–107PubMedCrossRef
18.
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5):591–602PubMedCrossRef
19.
Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, Park JY, Myoung SM, Kim dY, Chon CY, Han KH (2008) MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29(6):1192–1196PubMedCrossRef
20.
Freedman DA, Levine AJ (1999) Regulation of the p53 protein by the MDM2 oncoprotein–thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 59(1):1–7PubMed
21.
Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53(10 Suppl):2231–2234PubMed
22.
Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H (2007) MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 16(12):2717–2723PubMedCrossRef
23.
Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66(10):5104–5110PubMedCrossRef
24.
Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119(3):718–721PubMedCrossRef
25.
Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D’Andrea E, Nitti D, Amadori A, Bertorelle R (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98(4):285–288PubMedCrossRef
26.
Firoz EF, Warycha M, Zakrzewski J, Pollens D, Wang G, Shapiro R, Berman R, Pavlick A, Manga P, Ostrer H, Celebi JT, Kamino H, Darvishian F, Rolnitzky L, Goldberg JD, Osman I, Polsky D (2009) Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin Cancer Res 15(7):2573–2580PubMedCrossRef
27.
Taubert H, Bartel F, Greither T, Bache M, Kappler M, Kohler T, Bohnke A, Lautenschlager C, Schmidt H, Holzhausen HJ, Hauptmann S, Wurl P (2008) Association of HDM2 transcript levels with age of onset and prognosis in soft tissue sarcomas. Mol Cancer Res 6(10):1575–1581PubMedCrossRef
28.
Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Katongole-Mbidde E, Loquercio G, Buonaguro L, Buonaguro FM (2010) Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi’s sarcoma lesions during pre-AIDS and AIDS era. Virology 398(2):280–289PubMedCrossRef
29.
Jalilvand S, Tornesello ML, Buonaguro FM, Buonaguro L, Naraghi ZS, Shoja Z, Ziaee AA, Hamkar R, Shahmahmoodi S, Nategh R, Mokhtari-Azad T (2012) Molecular epidemiology of human herpesvirus 8 variants in Kaposi’s sarcoma from Iranian patients. Virus Res 163(2):644–649PubMedCrossRef
30.
Di V V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, Tornesello ML (2011) TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer 6:13CrossRef
31.
Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, Mecklin JP, Atula T, Kontio R, Makitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA (2005) The MDM2 promoter polymorphism SNP309T–>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42(9):694–698PubMedPubMedCentralCrossRef
32.
Horikawa Y, Nadaoka J, Saito M, Kumazawa T, Inoue T, Yuasa T, Tsuchiya N, Nishiyama H, Ogawa O, Habuchi T (2008) Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep 20(1):49–55PubMed
33.
Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q (2006) MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 27(10):2028–2033PubMedCrossRef
34.
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM (2010) MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 55(2):248–253PubMedPubMedCentralCrossRef
35.
Onat OE, Tez M, Ozcelik T, Toruner GA (2006) MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res 26(5A):3473–3475PubMed
36.
Terry K, McGrath M, Lee IM, Buring J, De VI (2008) MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomark Prev 17(4):983–986CrossRef
37.
Tornesello ML, Buonaguro L, Cristillo M, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Viviano E, Romano N, Katongole-Mbidde E, Buonaguro FM (2011) MDM2 and CDKN1A gene polymorphisms and risk of Kaposi’s sarcoma in African and Caucasian patients. Biomarkers 16(1):42–50PubMedCrossRef
38.
Liu G, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, Xu W, Su L, Asomaning K, Heist RS, Wain JC, Lynch TJ, Christiani DC (2010) p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. Dis Esophagus 23(1):36–39PubMedCrossRef
39.
Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Jin G, Liu J, Wang X, Wei Q, Shen H (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240(2):261–267PubMedCrossRef
40.
Pine SR, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, Shields PG, Harris CC (2006) MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 15(8):1559–1561PubMedCrossRef
41.
Wilkening S, Bermejo JL, Hemminki K (2007) MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 28(11):2262–2267PubMedCrossRef
42.
Friborg J Jr, Kong W, Hottiger MO, Nabel GJ (1999) p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402(6764):889–894. doi:10.​1038/​47266 PubMed
43.
44.
45.
Baresova P, Musilova J, Pitha PM, Lubyova B (2014) p53 tumor suppressor protein stability and transcriptional activity are targeted by Kaposi’s sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3. Mol Cell Biol 34(3):386–399PubMedPubMedCentralCrossRef
46.
Shin YC, Nakamura H, Liang X, Feng P, Chang H, Kowalik TF, Jung JU (2006) Inhibition of the ATM/p53 signal transduction pathway by Kaposi’s sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol 80(5):2257–2266PubMedPubMedCentralCrossRef
47.
Lee HR, Toth Z, Shin YC, Lee JS, Chang H, Gu W, Oh TK, Kim MH, Jung JU (2009) Kaposi’s sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. J Virol 83(13):6739–6747PubMedPubMedCentralCrossRef
48.
Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65(13):5481–5484PubMedCrossRef
49.
Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R (2007) MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 13(14):4123–4129PubMedCrossRef
50.
Asomaning K, Reid AE, Zhou W, Heist RS, Zhai R, Su L, Kwak EL, Blaszkowsky L, Zhu AX, Ryan DP, Christiani DC, Liu G (2008) MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res 14(12):4010–4015PubMedCrossRef
51.
Han JY, Lee GK, Jang DH, Lee SY, Lee JS (2008) Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 113(4):799–807PubMedCrossRef
Metadata
Title
MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients
Authors
Sajad Varmazyar
Sayed Mahdi Marashi
Zabihollah Shoja
Maria Lina Tornesello
Franco M. Buonaguro
Shohreh Shahmahmoodi
Zahra Safaie-Naraghi
Somayeh Jalilvand
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 2/2017
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-016-0491-9

Other articles of this Issue 2/2017

Medical Microbiology and Immunology 2/2017 Go to the issue

Original Investigation

iTRAQ-based quantitative proteomics reveals important host factors involved in the high pathogenicity of the H5N1 avian influenza virus in mice

Rapid Communication

Development of a high-throughput colorimetric Zika virus infection assay

Original Investigation

Using dendritic cells to evaluate how Burkholderia cenocepacia clonal isolates from a chronically infected cystic fibrosis patient subvert immune functions

Original Investigation

Human polyomavirus and human papillomavirus prevalence and viral load in non-malignant tonsillar tissue and tonsillar carcinoma

Original Investigation

Paracoccidioides brasiliensis induces cytokine secretion in epithelial cells in a protease-activated receptor-dependent (PAR) manner

Review

Dysbiosis a risk factor for celiac disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits